Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
复制标题
DOI：
10.1186/2193-1801-3-71
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Moskovitz M
中科院分区：
文献类型：
--
作者：
Fried G;Moskovitz M
本回顾性研究评估了中期复发评分®结果对雌激素受体阳性（ER+）早期浸润性乳腺癌辅助治疗决策的影响，比较了治疗建议前测试和实际治疗后测试。在纳入分析的111例患者中，78例（70.3%）接受激素治疗（HT）， 33例（29.7%）接受激素化疗（CHT）推荐的预检测。术前推荐使用CHT的患者的复发评分明显高于术前推荐使用HT的患者（中位数为24比22；P = 0.047； Mann-Whitney-Wilcoxon [MWW]检验）。检测后，24例患者（21.6%）的治疗与检测前的建议不同。在整个队列和患者亚组（按年龄、肿瘤大小和分级）中，术前推荐率和术后推荐率之间的差异无统计学意义（P < 0.17； McNemar检验）。在将队列分为两个复发评分亚类（中低，[18-25]；中高，[26-30]）后，16.5%的中低患者和34.4%的中高患者报告了治疗决策的变化（检测前推荐与检测后实际接受的治疗）。检测后，中低亚类别的CHT发生率降低（58%），中高亚类别的CHT发生率升高（64%）（两亚类别均P <0.01）。在逻辑回归分析中，复发评分是治疗决策改变的唯一显著预测因子（测试前推荐与测试后接受的实际治疗；P <0.01）。两组患者（HT到CHT， 11例；CHT到HT， 13例）之间唯一的显著差异是复发评分（中位数分别为28比20；P = 0.0014； MWW检验）。这些发现表明，中期复发评分结果提供了临床相关信息，并影响了ER +早期乳腺癌的治疗决策。
This retrospective study evaluated the impact of intermediate Recurrence Score® results on adjuvant treatment decisions in estrogen receptor-positive (ER+) early invasive breast cancer, comparing treatment recommendations pre-testing with actual treatments received post-testing. Of the 111 patients included in the analysis, 78 (70.3%) had hormonal therapy (HT) and 33 (29.7%) had chemohormonal therapy (CHT) recommendations pre-testing. The Recurrence Score was significantly higher in those with a pre-testing CHT recommendation compared with those with a pre-testing HT recommendation (median of 24 vs. 22; P = 0.047; Mann–Whitney–Wilcoxon [MWW] test). Post-testing, treatment of 24 patients (21.6%) was different from their pre-testing recommendation. The difference between CHT recommendation rate pre-testing and the rate of CHT received post-testing was nonsignificant for the entire cohort and for patients’ subgroups (by age, tumor size, and grade) (P >0.17; McNemar’s test). Following classification of the cohort into two Recurrence Score subcategories (low-intermediate, [18-25]; high-intermediate, [26-30]), changes in treatment decisions (pre-testing recommendations vs. actual treatments received post testing) were reported for 16.5% of low-intermediate and 34.4% of high-intermediate patients. Post-testing, the rate of CHT decreased (by 58%) in the low-intermediate subcategory and increased (by 64%) in the high-intermediate subcategory (P <0.01, both subcategories). In logistic regression analyses, the Recurrence Score subcategory was the only significant predictor of changes in treatment decisions (pre-testing recommendations vs. actual treatments received post testing; P <0.01). The only significant difference between the two subsets of patients with such a change (HT to CHT, 11 patients; CHT to HT, 13 patients) was the Recurrence Score (median of 28 vs. 20, respectively; P = 0.0014; MWW test). These findings demonstrate that intermediate Recurrence Score results provide clinically relevant information and impact treatment decisions in ER + early breast cancer.
登录
查看更多内容
影响因子：
2.5
作者：
Henry, Leonard R.;Stojadinovic, Alexander;Soballe, Peter W.
通讯作者：
Soballe, Peter W.
DOI：
10.1093/annonc/mds512
发表时间：
2013-03
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Eiermann W;Rezai M;Kümmel S;Kühn T;Warm M;Friedrichs K;Schneeweiss A;Markmann S;Eggemann H;Hilfrich J;Jackisch C;Witzel I;Eidtmann H;Bachinger A;Hell S;Blohmer J
通讯作者：
Blohmer J
影响因子：
45.3
作者：
Lo, Shelly S.;Mumby, Patricia B.;Albain, Kathy S.
通讯作者：
Albain, Kathy S.
影响因子：
5.8
作者：
Kamal, Arif H.;Loprinzi, Charles L.;Goetz, Matthew P.
通讯作者：
Goetz, Matthew P.
影响因子：
8.8
作者：
Holt S;Bertelli G;Humphreys I;Valentine W;Durrani S;Pudney D;Rolles M;Moe M;Khawaja S;Sharaiha Y;Brinkworth E;Whelan S;Jones S;Bennett H;Phillips CJ
通讯作者：
Phillips CJ